Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
Sponsor: Takeda
Summary
This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID). This survey will conduct in use of medical database called PIDJ2.
Official title: Post-marketing Database Survey: A Cohort Study to Evaluate the Safety of Cuvitru in Patients With Primary Immunodeficiency Using the PIDJ2 (Primary Immunodeficiency Database in Japan) Registry
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2025-02-17
Completion Date
2030-07-31
Last Updated
2026-02-20
Healthy Volunteers
No
Conditions
Interventions
Immune Globulin Subcutaneous (Human), 20% Solution
CUVITRU 20% Solution
Locations (1)
Takeda selected site
Tokyo, Tokyo, Japan